2025-11-13T10:05:21-08:00 2024-12-31 472626541 Cook & Company A Prof Actcy Corporation One Sansome St Ste 3500 San Francisco CA 94104 990 2024-01-01 261721868 Addario Lung Cancer Medical Institute ADDA 6505982857 1100 Industrial Road Suite 1 San Carlos CA 94070 Richard Erwin COO 2025-11-13 true true Douglas Cook PhDMPACPA P01521705 4156211112 2024 2025-03-06 01:10:19Z Ken Krantz 1100 Industrial Road Suite 1 San Carlos CA 94070 2719685 false X www.ALCMI.org X 2008 CA The Addario Lung Cancer Medical Institute ALCMI is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. 7 7 2 0 1321149 1559462 222957 309474 9463 45098 0 1553569 1914034 0 0 376196 425393 0 62781 736764 1159831 1112960 1585224 440609 328810 1490643 2244730 122812 551191 1367831 1693539 The Addario Lung Cancer Medical Institute ALCMI is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. false false 1349312 309374 Research - The Addario Lung Cancer Medical Institute (ALCMI) is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. ALCMI is a patient-founded, patient-focused research consortium. Its goal is to make lung cancer a chronically managed disease. ALCMI was created in 2008 to enable the collection and analysis of tissue and blood samples which are essential to research and to the development of individually tailored (and more effective) therapies. ALCMI is also a comprehensively contracted consortium with shared infrastructures (standardized contracts, data systems and biorepositories) and centrally coordinated scientific planning. Cont'd. at Schedule O 1349312 true true false false false false false false false false true false false false true false false false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 9 0 true 2 true false false false false false false false 0 false false false false false false false X 7 7 false false false false false false false true false false false true true true true true true false true false CA X Debi Beltramo 6505982857 1100 Industrial Road Suite 1 San Carlos CA 94070 X Richard Erwin Sr. Dir. Clinical Operations 40.00 0.00 221088 0 9783 Tony Addario Chair CEO 40.00 0.00 X X 0 0 0 Ken Krantz CEO 40.00 0.00 X X 0 0 0 Bonnie Addario Director 5.00 0.00 X 0 0 0 Bruce Gellman Director 0.46 0.00 X 0 0 0 Gary Ingenito Director 0.46 0.00 X 0 0 0 Steve Cavan Treasurer Director 0.46 0.00 X 0 0 0 Tom Krohn RPh MBA Director 0.46 0.00 X 0 0 0 221088 9783 1 false true false Harper Clinical Res SrvcsLLC 53 Stono Drive Greenville SC 29609 Clinical consultants 198000 Wayne Niemi 833 Cordova Street Burbank CA 91505 Marketing Communications 117576 2 1559462 1559462 Fees for Services 900099 309474 309474 309474 28749 28749 0 0 0 822000 805651 16349 16349 16349 0 0 0 0 1914034 309474 45098 X 0 0 0 0 230871 173153 57718 0 155338 123711 31627 0 13628 8681 4947 25556 19313 6243 0 1593 1593 42568 42568 0 0 0 1002242 935767 6524 59951 0 13911 9848 4063 0 0 21991 21991 35987 25308 10094 585 0 0 0 0 384 384 27002 27002 Miscellaneous 14153 8308 5121 724 Shared cost allocation 0 45223 -46744 1521 0 1585224 1349312 173131 62781 250000 8547 309655 687172 0 51862 19793 0 0 0 0 56273 583783 4751 4269 866 482 815025 856982 0 0 0 6962 87971 1490643 2244730 115850 174504 287846 6962 88841 122812 551191 X 950892 156385 416939 1537154 1367831 1693539 1490643 2244730 328810 -3102 X false false false X 745843 876750 622909 1321149 1559642 5126293 0 0 745843 876750 622909 1321149 1559642 5126293 296703 4829590 122 147 90 9463 28749 38571 0 0 5164864 1821801 0.93510 0.92040 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4751 4269 482 482 Lease liabilities 88841 88841 X false false false false false false false false false Richard Erwin Sr. Dir. Clinical Operations 221088 9783 230871 Tony Addario CEO/Chair 21991 Office rent false Schedule L, Part V Supplemental Information Tony Addario, Chair/CEO, of filing entity has a beneficial interest in Brittan Avenue, LLC, which is the landlord of the filing entity. Form 990, Part VI, Section B, Line 11b An electronic copy of Form 990 is provided to the Board of Directors for review before filing. Form 990, Part VI, Section B, Line 12c The Conflict of Interest Committee is a standing committee and shall consist of no fewer than three directors. The Conflict of Interest Committee is responsible for identifying, investigating and advising the Board with respect to existing and/or potential transactions that may benefit the private interest of a director or Officer of the Corporation in accordance with the Conflict of Interest Policy of the Corporation annexed to the by-laws as Annex A, interpreting the Conflicts of Interest Policy, reporting to the Board on its actions no less than annually, and conducting periodic reviews of the Corporation's activities to identify potential and/or actual Interested Party transactions. Subject to the provisions of this Section 5.4 and Annex A, the Conflict of Interest Committee shall have such additional purpose, membership, general and specific functions and responsibilities as may be provided for in any committee charter of the Conflict of Interest Committee approved by the entire Board. Form 990, Part VI, Section B, Line 15b ALCMI's CEO is not compensated. Regarding the compensation paid to the Senior Director of Clinical Operations, the CEO conducts reviews, checks Non Profit compensation reports from CA NonProfits. The board also reviews. This process occurred during 2020. Form 990, Part VI, Section C, Line 19 The Organization shall make available its governing documents, conflict of interest policy and financial statements upon request. Form 990, Part III, 4a- Program Expenses (Cont'd. from page 2) ALCMI's researchers are pooling their knowledge, specimens and data in order to improve the understanding of the molecular bases of lung cancer and to accelerate the development and delivery of much more effective, targeted drugs and treatments tailored to individual patient types. ALCMI has developed, conducted, and published a number of innovative research studies that would otherwise not have existed: 1) CASTLE: a prospective, longitudinal, multi-center study with serial biobanked advanced stage lung cancer specimens that are also annotated with clinical/molecular data. 2) INHERIT EGFR T790M: a prospective study on germline biology in high-risk families; to identify specific inherited genetic markers indicating risk of developing lung cancer. 3) Genomics of Young Lung Cancer (GoYLC): a prospectively performed comprehensive genomic profiling to determine whether young lung cancers harbor a distinctive spectrum of genetic mutations, and therefore unique treatment strategies (peer-reviewed paper published in 2021, Journal of Thoracic Oncology). Other studies in progress are 4) Epidemiology of Young Lung Cancer (EoYLC): a remote decentralized survey study designed to identify lifestyle, environmental, and family/genetic risk factors associated with the development of lung cancer under the age of 50, and any possible connection to specific cancer-driving mutations. Data from this trial has now been presented at several national and international cancer conferences. The sponsor-funder of this trial has closed enrollment, and results from this trial have recently been submitted for feature at the 2026 American Academy of Cancer Research (AACR) conference. Plans are also to submit results to the 2026 World Conference Lung Cancer (Sept, Seoul). 5) SPACEWALK: a study to investigate the relationship between specific ALK resistance mutations and specific next generation ALK TKI therapies received before progression. The results of this trial were published in the Journal of Thoracic Oncology. 6) BEACON-LUNG: a multicenter study collecting serum, plasma, tissue, and CT images from patients receiving pembrolizumab or pembrolizumab plus carboplatin-based chemotherapy to help identify patients who may benefit from a more aggressive triplet treatment regimen. This test utilizes mass spectrometry with machine learning and was developed by Biodesix, Inc. to classify patients as responders or non-responders, which could help identify patients who may benefit from a triplet treatment regimen. This trial was closed prematurely by the sponsor-funder. 7) ENIGMA+: a remote decentralized study collecting tissue and sputum specimens and clinical outcome data across patients diagnosed with ALK+ mutation NSCLC. ALCMI recently achieved the enrollment goal for this study. 8) SPARK: a remote decentralized study collecting blood specimens and clinical outcome data across patients diagnosed with KRAS mutation NSCLC. The sponsor-funder of this trial has closed enrollment, and results from this trial have recently been submitted for feature at the 2026 American Academy of Cancer Research (AACR) conference. 9) TURN-AROUND-TIME: a regional, community hospital-based project aimed at establishing de novo Next Generation Sequencing (NGS) testing in facilities that heretofore rely on external "send-out" lab testing, and a research trial to test the hypothesis that putting NGS data into the hands of treating oncologists sooner can improve downstream patient treatment outcomes. 10) INHERIT 2.0: a new prospective study on germline biology in high-risk families using a more advanced panel of biomarkers; to identify specific inherited genetic markers indicating risk of developing lung cancer. 11) SUCCEED: a pilot feasibility trial to determine the viability and barriers of enrolling patients diagnosed with Small Cell Lung cancer (SCLC) into a remote decentralized format study.